Millennium Pharmaceuticals announced positive results from several early studies of its multiple myeloma drug Velcade, including one that found when used in combination with Celgene's Revlimid, the drug stopped the spread of cancer in 87% of newly diagnosed myeloma patients. The findings have led to speculation over whether Millennium and Celgene might partner on future treatments.

Full Story:

Related Summaries